Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology
July 25th, 2025 2:30 PM
By: Advos Staff Reporter
Nutriband Inc. is pioneering in the development of abuse-deterrent transdermal patches, with its AVERSA Fentanyl and Buprenorphine candidates poised to address critical public health needs and generate significant sales.
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the pharmaceutical industry with its innovative abuse-deterrent drug delivery platform. The company's AVERSA Fentanyl patch, potentially the first of its kind, aims to combat the abuse and misuse of transdermal fentanyl patches, with projected peak annual U.S. sales between $80 and $200 million. Similarly, AVERSA Buprenorphine is expected to achieve peak U.S. sales of $70 to $130 million upon approval. These developments are crucial in addressing the opioid crisis by reducing the risk of accidental exposure and deterring abuse.
The scalability of Nutriband's platform and the impending global patent protection for its technology underscore the company's potential to make a lasting impact on public health. For more information on Nutriband's advancements, visit https://ibn.fm/8PgtJ.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
